Published :
Tables : 52
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-U4452
Antibody Drug Conjugate Market is poised to value USD 16820.81 million by 2028 end at a CAGR of 16.4% during the forecast period 2022 to 2028. Antibody drug conjugates consist of three main components: an antibody specific to the target antigen, an antigen with a restricted expression on normal cells, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. In addition to their therapeutic potential, antibody-drug conjugates pose both technical and developmental challenges. The use of antibody-drug conjugates is considered to be the new wave of therapeutic agents. These drugs combine monoclonal antibody targeting abilities with cytotoxic drugs' ability to kill specific cells. Technology advancements have led to the success of this technology. The new class of therapeutic agents, antibody-drug conjugates, is becoming increasingly popular among both large and small pharmaceutical companies. Despite being used for treating acute myelogenous leukemia, a clinical trial found the drug only increased mortality rates and provided no benefit over conventional therapies. Thus, only two antibody drug conjugates are approved in the market. Technological advancements will drive the global demand for antibody-drug conjugates. The increasing prevalence of cancer, the increasing aging population, and the increase in obesity are driving the market. The growing number of antibody-drug conjugates research activities, preclinical research, and research on advanced drug discoveries, together with growing collaboration between research institutes, biotechnology companies, and pharmaceutical companies, is also driving the market. Despite the recent growth in antibody-drug conjugates technology, the number of companies developing these methods has not changed significantly. It is expected that pharmaceutical and biotechnology companies will increase their investment in the market. FutureWise Market Research has instantiated a report that provides an intricate analysis of Antibody Drug Conjugate Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market. According to the research study conducted by FutureWise research analysts, the Antibody Drug Conjugate Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Antibody Drug Conjugate Market: • Seattle Genetics • ImmunoGen, Inc. • Roche Holding AG • Genentech • Concortis Biotherapeutics • AGENSYS, INC. • Antikor • Immunomedics • Pfizer Inc. • Celldex Therapeutics • Millennium Pharmaceuticals • AbbVie Inc. • Bayer HealthCare • Astellas Pharma/Agensys • Progenics Pharmaceuticals • Mersana Therapeutics • Synthon • Heidelberg Pharma • Oxford BioTherapeutics (Note: The list of the major players will be updated with the latest market scenario and trends) Antibody Drug Conjugate Market Segmentation: By Type • Monoclonal Antibodies • Linker • Drug/Toxin • Others By Application • Leukemia o Acute Myeloid Leukemia (AML) o Chronic Myeloid Leukemia (CML) o Acute Lymphocytic Leukemia (ALL) o Chronic Lymphocytic Leukemia (CLL) • Prostate Cancer • Kidney Cancer • Pancreas Cancer • Ovary Cancer • Glioblastoma • Lung Cancer • Colon Cancer • Breast Cancer • Skin Cancer • Solid Tumors • Multiple Myeloma • Lymphoma By Product • Adcertis • Kadcyla • Others By Technology • ImmunoGen Technology • Seattle Genetics Technology • Immunomedics Technology • Others By End User • Hospitals • Specialized Cancer Centers • Academic Research Institutes • Biopharmaceutical Companies • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa Antibody Drug Conjugate Market Sample Video: Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the Antibody Drug Conjugate Market By Type, By Application, By Product, By Technology, By End User and By Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Antibody drug conjugates consist of three main components: an antibody specific to the target antigen, an antigen with a restricted expression on normal cells, a cytotoxic agent designed to kill target cancer cells, and a chemical linker for attaching the cytotoxic agent to the antibody. In addition to their therapeutic potential, antibody-drug conjugates pose both technical and developmental challenges. The use of antibody-drug conjugates is considered to be the new wave of therapeutic agents. These drugs combine monoclonal antibody targeting abilities with cytotoxic drugs' ability to kill specific cells. Technology advancements have led to the success of this technology. The new class of therapeutic agents, antibody-drug conjugates, is becoming increasingly popular among both large and small pharmaceutical companies. Despite being used for treating acute myelogenous leukemia, a clinical trial found the drug only increased mortality rates and provided no benefit over conventional therapies. Thus, only two antibody drug conjugates are approved in the market. Technological advancements will drive the global demand for antibody-drug conjugates. The increasing prevalence of cancer, the increasing aging population, and the increase in obesity are driving the market. The growing number of antibody-drug conjugates research activities, preclinical research, and research on advanced drug discoveries, together with growing collaboration between research institutes, biotechnology companies, and pharmaceutical companies, is also driving the market. Despite the recent growth in antibody-drug conjugates technology, the number of companies developing these methods has not changed significantly. It is expected that pharmaceutical and biotechnology companies will increase their investment in the market.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Antibody Drug Conjugate Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Antibody Drug Conjugate Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.
Major players included in the Antibody Drug Conjugate Market: • Seattle Genetics • ImmunoGen, Inc. • Roche Holding AG • Genentech • Concortis Biotherapeutics • AGENSYS, INC. • Antikor • Immunomedics • Pfizer Inc. • Celldex Therapeutics • Millennium Pharmaceuticals • AbbVie Inc. • Bayer HealthCare • Astellas Pharma/Agensys • Progenics Pharmaceuticals • Mersana Therapeutics • Synthon • Heidelberg Pharma • Oxford BioTherapeutics (Note: The list of the major players will be updated with the latest market scenario and trends)
Antibody Drug Conjugate Market Segmentation: By Type • Monoclonal Antibodies • Linker • Drug/Toxin • Others By Application • Leukemia o Acute Myeloid Leukemia (AML) o Chronic Myeloid Leukemia (CML) o Acute Lymphocytic Leukemia (ALL) o Chronic Lymphocytic Leukemia (CLL) • Prostate Cancer • Kidney Cancer • Pancreas Cancer • Ovary Cancer • Glioblastoma • Lung Cancer • Colon Cancer • Breast Cancer • Skin Cancer • Solid Tumors • Multiple Myeloma • Lymphoma By Product • Adcertis • Kadcyla • Others By Technology • ImmunoGen Technology • Seattle Genetics Technology • Immunomedics Technology • Others By End User • Hospitals • Specialized Cancer Centers • Academic Research Institutes • Biopharmaceutical Companies • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
Antibody Drug Conjugate Market Sample Video:
Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants
FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth
Objectives of the Study: • To provide with an exhaustive analysis on the Antibody Drug Conjugate Market By Type, By Application, By Product, By Technology, By End User and By Region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Antibody Drug Conjugate Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Antibody Drug Conjugate Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Antibody Drug Conjugate Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Antibody Drug Conjugate Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Monoclonal Antibodies 7.2. Linker 7.3. Drug/Toxin 7.4. Others 8. Antibody Drug Conjugate Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Leukemia 8.1.1. Acute Myeloid Leukemia (AML) 8.1.2. Chronic Myeloid Leukemia (CML) 8.1.3. Acute Lymphocytic Leukemia (ALL) 8.1.4. Chronic Lymphocytic Leukemia (CLL) 8.2. Prostate Cancer 8.3. Kidney Cancer 8.4. Pancreas Cancer 8.5. Ovary Cancer 8.6. Glioblastoma 8.7. Lung Cancer 8.8. Colon Cancer 8.9. Breast Cancer 8.10.Skin Cancer 8.11.Solid Tumors 8.12.Multiple Myeloma 8.13.Lymphoma 8.14.Others 9. Antibody Drug Conjugate Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Adcertis 9.2. Kadcyla 9.3. Others 10. Antibody Drug Conjugate Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. ImmunoGen Technology 10.2. Seattle Genetics Technology 10.3. Immunomedics Technology 10.4. Others 11. Antibody Drug Conjugate Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Hospitals 11.2. Specialized Cancer Centers 11.3. Academic Research Institute 11.4. Biopharmaceutical Companies 11.5. Others 12. North America Antibody Drug Conjugate Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028 13. Latin America Antibody Drug Conjugate Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028 14. Europe Antibody Drug Conjugate Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028 15. Asia Pacific Antibody Drug Conjugate Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 16. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028 17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix 18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Seattle Genetics 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. ImmunoGen, Inc. 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Roche Holding AG 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Genentech 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Concortis Biotherapeutics 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. AGENSYS, INC. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Antikor 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Immunomedics 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Pfizer Inc. 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10.Celldex Therapeutics 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11.Millennium Pharmaceuticals 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12.AbbVie Inc. 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13.Bayer HealthCare 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14.Astellas Pharma/Agensys 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15.Progenics Pharmaceuticals 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16.Mersana Therapeutics 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17.Synthon 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18.Heidelberg Pharma 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19.Oxford BioTherapeutics 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview 19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations 20. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Antibody Drug Conjugate Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Antibody Drug Conjugate Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Antibody Drug Conjugate Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Antibody Drug Conjugate Market, By Type Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Monoclonal Antibodies 7.2. Linker 7.3. Drug/Toxin 7.4. Others
8. Antibody Drug Conjugate Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Leukemia 8.1.1. Acute Myeloid Leukemia (AML) 8.1.2. Chronic Myeloid Leukemia (CML) 8.1.3. Acute Lymphocytic Leukemia (ALL) 8.1.4. Chronic Lymphocytic Leukemia (CLL) 8.2. Prostate Cancer 8.3. Kidney Cancer 8.4. Pancreas Cancer 8.5. Ovary Cancer 8.6. Glioblastoma 8.7. Lung Cancer 8.8. Colon Cancer 8.9. Breast Cancer 8.10.Skin Cancer 8.11.Solid Tumors 8.12.Multiple Myeloma 8.13.Lymphoma 8.14.Others
9. Antibody Drug Conjugate Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Adcertis 9.2. Kadcyla 9.3. Others
10. Antibody Drug Conjugate Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. ImmunoGen Technology 10.2. Seattle Genetics Technology 10.3. Immunomedics Technology 10.4. Others
11. Antibody Drug Conjugate Market, By End User Historical Analysis and Forecast 2022-2028 (USD Million) 11.1. Hospitals 11.2. Specialized Cancer Centers 11.3. Academic Research Institute 11.4. Biopharmaceutical Companies 11.5. Others
12. North America Antibody Drug Conjugate Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. U.S.A 12.2.2. Canada 12.2.3. Mexico 12.3. Market Size (USD Million) Forecast for North America 2022-2028
13. Latin America Antibody Drug Conjugate Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Brazil 13.2.2. Venezuela 13.2.3. Argentina 13.2.4. Rest of Latin America 13.3. Market Size (USD Million) Forecast for Latin America 2022-2028
14. Europe Antibody Drug Conjugate Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Germany 14.2.2. U.K 14.2.3. France 14.2.4. Italy 14.2.5. Spain 14.2.6. Russia 14.2.7. Poland 14.2.8. Rest of Europe 14.3. Market Size (USD Million) Forecast for Europe 2022-2028
15. Asia Pacific Antibody Drug Conjugate Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. Japan 15.2.2. China 15.2.3. India 15.2.4. Australia and New Zealand 15.2.5. ASEAN 15.2.6. Rest of Asia Pacific 15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
16. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 16.1. Introduction 16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 16.2.1. GCC 16.2.2. Israel 16.2.3. South Africa 16.2.4. Rest of MEA 16.3. Market Size (USD Million) Forecast for MEA 2022-2028
17. Market Share Analysis and Competitive Landscape 17.1. Global Landscape - Key Players, Revenue and Presence 17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 17.3. Global Emerging Companies 17.4. North America - Market Share Analysis and Key Regional Players 17.5. Europe - Market Share Analysis and Key Regional Players 17.6. Asia Pacific - Market Share Analysis and Key Regional Players 17.7. Global Key Player - Growth Matrix
18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 18.1. Seattle Genetics 18.1.1. Company Overview 18.1.2. Product Portfolio 18.1.3. SWOT Analysis 18.1.4. Financial Overview 18.1.5. Strategic Overview 18.2. ImmunoGen, Inc. 18.2.1. Company Overview 18.2.2. Product Portfolio 18.2.3. SWOT Analysis 18.2.4. Financial Overview 18.2.5. Strategic Overview 18.3. Roche Holding AG 18.3.1. Company Overview 18.3.2. Product Portfolio 18.3.3. SWOT Analysis 18.3.4. Financial Overview 18.3.5. Strategic Overview 18.4. Genentech 18.4.1. Company Overview 18.4.2. Product Portfolio 18.4.3. SWOT Analysis 18.4.4. Financial Overview 18.4.5. Strategic Overview 18.5. Concortis Biotherapeutics 18.5.1. Company Overview 18.5.2. Product Portfolio 18.5.3. SWOT Analysis 18.5.4. Financial Overview 18.5.5. Strategic Overview 18.6. AGENSYS, INC. 18.6.1. Company Overview 18.6.2. Product Portfolio 18.6.3. SWOT Analysis 18.6.4. Financial Overview 18.6.5. Strategic Overview 18.7. Antikor 18.7.1. Company Overview 18.7.2. Product Portfolio 18.7.3. SWOT Analysis 18.7.4. Financial Overview 18.7.5. Strategic Overview 18.8. Immunomedics 18.8.1. Company Overview 18.8.2. Product Portfolio 18.8.3. SWOT Analysis 18.8.4. Financial Overview 18.8.5. Strategic Overview 18.9. Pfizer Inc. 18.9.1. Company Overview 18.9.2. Product Portfolio 18.9.3. SWOT Analysis 18.9.4. Financial Overview 18.9.5. Strategic Overview 18.10.Celldex Therapeutics 18.10.1. Company Overview 18.10.2. Product Portfolio 18.10.3. SWOT Analysis 18.10.4. Financial Overview 18.10.5. Strategic Overview 18.11.Millennium Pharmaceuticals 18.11.1. Company Overview 18.11.2. Product Portfolio 18.11.3. SWOT Analysis 18.11.4. Financial Overview 18.11.5. Strategic Overview 18.12.AbbVie Inc. 18.12.1. Company Overview 18.12.2. Product Portfolio 18.12.3. SWOT Analysis 18.12.4. Financial Overview 18.12.5. Strategic Overview 18.13.Bayer HealthCare 18.13.1. Company Overview 18.13.2. Product Portfolio 18.13.3. SWOT Analysis 18.13.4. Financial Overview 18.13.5. Strategic Overview 18.14.Astellas Pharma/Agensys 18.14.1. Company Overview 18.14.2. Product Portfolio 18.14.3. SWOT Analysis 18.14.4. Financial Overview 18.14.5. Strategic Overview 18.15.Progenics Pharmaceuticals 18.15.1. Company Overview 18.15.2. Product Portfolio 18.15.3. SWOT Analysis 18.15.4. Financial Overview 18.15.5. Strategic Overview 18.16.Mersana Therapeutics 18.16.1. Company Overview 18.16.2. Product Portfolio 18.16.3. SWOT Analysis 18.16.4. Financial Overview 18.16.5. Strategic Overview 18.17.Synthon 18.17.1. Company Overview 18.17.2. Product Portfolio 18.17.3. SWOT Analysis 18.17.4. Financial Overview 18.17.5. Strategic Overview 18.18.Heidelberg Pharma 18.18.1. Company Overview 18.18.2. Product Portfolio 18.18.3. SWOT Analysis 18.18.4. Financial Overview 18.18.5. Strategic Overview 18.19.Oxford BioTherapeutics 18.19.1. Company Overview 18.19.2. Product Portfolio 18.19.3. SWOT Analysis 18.19.4. Financial Overview 18.19.5. Strategic Overview
19. Pre and Post COVID-19 Impact 19.1. Positive influence on the healthcare industry 19.2. The financial disruption of the manufacturing sector 19.3. Impact of COVID-19 on emerging companies 19.4. Significant mandates in the healthcare regulations initiated by administrations 19.5. The overall economic slowdown of the developing and developed nations
20. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics